問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Thoracic Surgery

Division of Hematology & Oncology

Chung Shan Medical University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間:2023-09-19

張基晟Chang, Gee-chen
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

篩選

List

115Cases

2015-11-01 - 2025-08-29

Phase III

Completed
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Nivolumab

Participate Sites
5Sites

Terminated5Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2008-10-01 - 2010-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-01-01 - 2024-11-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2009-04-15 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-11-14 - 2009-12-29

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-09-29 - 2013-12-16

Phase II

A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MM-121(SAR256212)

Participate Sites
6Sites

Terminated6Sites

2007-09-01 - 2008-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites